Kaigene Enters into Exclusive Licensing Agreement with Taisho Pharmaceutical for Next-Generation Autoimmune Asset KG006 in Japan

Key Highlights: Taisho Pharmaceutical secures exclusive rights to clinically develop, register, and commercialize Kaigene's next-generation FcRn inhibitor, KG006, in Japan. Kaigene will receive a $5 million upfront payment and is eligible for up to a combined total of $22 million and...